The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm
The approval of tagraxofusp established a foundation for targeted therapy in BPDCN and demonstrated high response rates, leading to the development of additional antibody - drug conjugates and cellular therapies targeting CD123. Other promising investigational targeted approaches may include BCL2 inhibitors, proteasome inhibitors, and therapies directed against surface antigens such as CD38 and CD303, as well as bromodomain and extraterminal (BET) inhibitors. Collectively, these strategies represent important advances that may significantly improve the historically poor outcomes associated with BPDCN.
Authors
- Maxim Norkin (ORCID: https://orcid.org/0000-0001-6048-7760)
- Zohra Nooruddin (ORCID: https://orcid.org/0000-0003-4659-4310)
- Matthew L. Ulrickson (ORCID: https://orcid.org/0000-0002-1458-7813)
- N. Pemmaraju
- Melissa L. Larson
- Tülin Budak-Alpdoǧan (ORCID: https://orcid.org/0000-0001-6498-9119)
- Suki Subbiah (ORCID: https://orcid.org/0000-0002-1192-0879)
- C DAVIS (ORCID: https://orcid.org/0000-0001-8128-5340)
- Leonard C. Alsfeld (ORCID: https://orcid.org/0000-0002-6512-4587)
- Sumeet Bhatia
- Roberta S. Azevedo
- Adolfo De La Fuente
- Laura Finn
Institutions
- Rush University Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- The University of Texas at San Antonio Health Science Center (US)
- Ochsner Medical Center (US)
- Cooper University Hospital (US)
- Baptist Cancer Center (US)
- Baptist Medical Center Jacksonville (US)
- Community Health Network (US)
- Baton Rouge Clinic (US)
- MD Anderson Cancer Center Madrid (ES)
- Banner MD Anderson Cancer Center
Publication Details
- Journal
- Expert Opinion on Biological Therapy
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1080/14712598.2025.2610291
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00